QIM
ITCI

Quantitative Investment Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Quantitative Investment Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,800
Closed -$226K – 922
2018
Q2 		$226K Sell
12,800
-13,200
-51% -$268K ﹤0.01% 688
2018
Q1 		$547K Buy
+26,000
New +$506K 0.01% 644

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Quantitative Investment Management's ITCI Position: Q3 2018 in Review

Quantitative Investment Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2018, closing a stake of 12,800 shares — an estimated $226K sold.

Quantitative Investment Management first reported a position in ITCI in Q1 2018 and held it in 2 quarters. The position peaked at $547K in Q1 2018. 131 funds tracked by Wall St. Rank hold ITCI as of Q3 2018.

  • Quantitative Investment Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2018 after selling out during the quarter.
  • Quantitative Investment Management sold 12,800 Intra-Cellular Therapies Inc. shares in Q3 2018, an estimated $226K.
  • Quantitative Investment Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2018 and held it in 2 quarters.
  • Quantitative Investment Management's Intra-Cellular Therapies Inc. position peaked at $547K in Q1 2018.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2018.

Based on Quantitative Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.